Advertisement

Topics

Latest Top Pharmaceutical Companies in Japan NewsRSS

15:00 EDT 28th September 2016 | BioPortfolio

Working Mother Magazine Names Astellas Among 100 Best Companies in the US Across All Industries

NORTHBROOK, Ill., Sept. 28, 2016 /PRNewswire/ -- Astellas was named one of Working Mother Magazine's 100 Best Companies in the U.S. for its commitment to establishing a corporate culture supportive of working moms and their families. The 100 Best Companies is featured in the October/November issue of Working Mother and on workingmother.com. This marks Astellas' second consecutive appearance...

#jobs #lifescience Digital Communications Specialist

// MA-Cambridge, Position Description: Seeking a dynamic individual to develop and maintain content across multiple external websites as well as manage daily operations of Takeda Oncology’s social media channels. The position reports to the Associate Director, Digital and Internal Communications, … Continue reading → Cet article #jobs #lifescience Digital Communications Specialis...

Amgen's Kyprolis Fails Phase III Multiple Myeloma Trial

Amgen acknowledged today that its Kyprolis® (carfilzomib) failed a Phase III trial comparing the marketed cancer drug to Velcade® (bortezomib) in combination with melphalan and prednisone in newly diagnosed multiple myeloma patients. Kyprolis missed its primary endpoint in the Phase III CLARION trial of superior progression-free survival (PFS) to Velcade—marketed in the U.S. by T...

Amgen's Kyprolis Fails Phase III Melanoma Trial

Amgen acknowledged today that its Kyprolis® (carfilzomib) failed a Phase III trial comparing the marketed cancer drug to Velcade® (bortezomib) in combination with melphalan and prednisone in newly diagnosed multiple melanoma patients. Kyprolis missed its primary endpoint in the Phase III CLARION trial of superior progression-free survival (PFS) to Velcade—marketed in the U.S. by ...

Amgen's Kyprolis Fails Phase III Melanoma Trial vs. Takeda's Velcade

Amgen acknowledged today that its Kyprolis® (carfilzomib) failed a Phase III trial comparing the marketed cancer drug to Velcade® (bortezomib) in combination with melphalan and prednisone in newly-diagnosed multiple melanoma patients. Kyprolis missed its primary endpoint in the Phase III CLARION trial of superior progression-free survival (PFS) to Velcade—marketed in the U.S. by ...

Takeda Named To 2016 Working Mother "100 Best Companies" For Leadership In Creating Progressive Programs To Support Working Families

DEERFIELD, Ill., Sept. 27, 2016 /PRNewswire/ -- Working Mother magazine today recognized Takeda as one of the 2016 "Working Mother 100 Best Companies" for its outstanding leadership in creating progressive programs for its work force, in the areas of advancement of women, flexibility, child care and paid parental leave. The 100 Best Companies are featured in the October/November issue of Working M...

Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer

TOKYO, PARSIPPANY, N.J., and MUNICH, Sept. 27, 2016 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that safety and preliminary efficacy phase 1 data evaluating DS-8201a, a novel HER2-targeting antibody drug conjugate, will be presented during a late-breaking poster discussion session during the European Society for Medical Oncology (ESMO) 2016 Congress ...

Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb

SAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at 9:00 a.m. Eastern Time (ET)/6:00 a.m. Pacific Time (PT) on Tuesday, September 27, 2016.  A live audio-only Webcast of the conference call can be ac...

Eisai Submits Supplemental Application to FDA for Use of its Antiepileptic Drug FYCOMPA® (perampanel) as Monotherapy for the Treatment of Partial Onset Seizures

WOODCLIFF LAKE, N.J., Sept. 26, 2016 /PRNewswire/ -- Eisai Inc. announced today that it has submitted a supplemental application to the U.S. Food and Drug Administration (FDA) for a proposed label change for its antiepileptic drug FYCOMPA® (perampanel) CIII which would include use as monotherapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized sei...

Technetium-99m Market to be Worth US$636.1 Million by 2026; Changing Disease Profile Responsible for Rising Demand in Middle East and Africa: Transparency Market Research

ALBANY, New York, September 23, 2016 /PRNewswire/ -- Some of the leading companies operating in the Middle East and Africa technetium-99m market are General Electric Company, Sumitomo Heavy Industries, Ltd., Siemens Healthineers, Advanced Cyclotron Systems, Inc., and IBA. Transparency Market Research finds that most companies in this avenue are focused on presenting a diverse and techno...

Lundbeck-Otsuka Alzheimer's Candidate Fails Phase III Trial

Lundbeck has acknowledged that the Alzheimer’s candidate idalopirdine, being developed through a partnership with Otsuka Pharmaceutical, has failed its first Phase III trial by failing to show efficacy in patients with mild to moderate forms of the disease. Both dosages of idalopirdine used in the STARSHINE trial missed the study’s primary endpoint of a reduction in the Alzheimer&#...

New #ThisIsMBC Campaign Seeks to Raise Awareness of Metastatic Breast Cancer by Encouraging People with This Rarely Discussed, Deadly Stage of the Disease to Share Their Experiences

ANNAPOLIS, Md. and WOODCLIFF LAKE, N.J., Sept. 22, 2016 /PRNewswire/ -- "The cancer has spread. We can offer you treatment, but ultimately, it is incurable." A metastatic breast cancer (MBC) diagnosis comes with many medical, practical and emotional challenges as patients adjust to their new reality. For many, this terminal diagnosis can lead to significant distress, with feelings of shock an...

Allergic Rhinitis Drugs Market Forecast 2016-2026

LONDON, September 22, 2016 /PRNewswire/ -- Report Details   What can be expected from the Allergic Rhinitis Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.   Our 240-page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in...

Takeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in Central Nervous System

Osaka, Japan and Nantes, France, September 21 2016 – Takeda Pharmaceutical Company Limited (TSE: 4502) and Affilogic today jointly announced that the companies have entered into a research collaboration to explore using Affilogic’s proprietary Nanofitins® platform in therapies t

Takeda has been selected for the seventh consecutive year for Dow Jones Sustainability Asia Pacific Index

Osaka, Japan, September 21, 2016 --- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that for the seventh consecutive year it has been selected for the Dow Jones Sustainability Asia Pacific Index ("DJSI Asia Pacific"), which is one of the world foremost indices for Socially Respons

Takeda and Zydus Cadila partner to address the global threat of Chikungunya

Osaka, Japan and Ahmedabad, India, September 21, 2016 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Zydus Cadila today announced a partnership to tackle chikungunya, an emerging infectious disease in Africa, Asia and the Indian subcontinent. In recent decades

Myths and Truths About Thyroid Cancer Educational Initiative Honors Thyroid Cancer Awareness Month with Launch of New #TruthAboutTC Social Media Challenge

WOODCLIFF LAKE, N.J., Sept. 21, 2016 /PRNewswire/ -- A thyroid cancer diagnosis can lead to significant distress as patients and caregivers cope with various medical, emotional and economic challenges, as survivors, patients and caregivers have attested. Yet because the majority of thyroid cancers can be successfully treated with surgery and radioactive iodine, the notion exists that thyroid ...

Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association

WOODCLIFF LAKE, N.J., Sept. 21, 2016 /PRNewswire/ -- Eisai Inc. announced today the presentation of abstracts at the 86th Annual Meeting of the American Thyroid Association (ATA) that highlight an investigational Phase 2 trial currently recruiting patients with anaplastic thyroid cancer, an aggressive, rare form of the disease, and a real-world quality of survival analysis in patients with lo...

ZappRx Hires Biopharmaceutical Industry Leader as Chief Operating Officer

BOSTON, Sept. 20, 2016 /PRNewswire/ -- ZappRx (zapprx.com), a digital specialty prescribing platform focused on increasing patient access to therapy, today announced the hiring of Sandy DiCesare as Chief Operating Officer. DiCesare most recently served as VP of Commercial Operations at Takeda Oncology. She joined Millennium Pharmaceuticals in 1998 as VP, Information Technology and then served as V...

Vical-Astellas CMV Vaccine Candidate Fails Phase II Study

Vical and Astellas Pharma said today that their ASP0113 failed a Phase II trial comparing the cytomegalovirus (CMV) vaccine candidate to placebo in kidney transplant patients receiving an organ from a CMV-seropositive donor. ASP0113 did not meet the study’s primary endpoint—the proportion of patients having CMV viremia, defined as a plasma viral load of ≥1000 IU/mL by central la...

Avara Pharmaceutical Services Celebrates One Year Since Launch With Arecibo (PR) Site and Acquisition of Shannon, Ireland Site

NORWALK, Conn., Sept. 19, 2016 /PRNewswire/ -- Avara Pharmaceutical Services, Inc. ("Avara") recently celebrated their first year since the acquisition of their Arecibo, Puerto Rico, site from Merck.  Since that time, Avara, headquartered in Norwalk, CT, (USA), now has four manufacturing facilities with about 800 employees in 4 countries.  Most recently, Avara announced the acquisitio...

Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients

SAN DIEGO and TOKYO, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) and Astellas Pharma Inc. (TOKYO:4503) today announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, ASP0113, versus placebo in kidney transplant patients receiving an organ from a CMV-seropositive dono...

Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO (ixazomib), the First Oral Proteasome Inhibitor, for Use in Patients with Multiple Myeloma

For a conditional approval, Takeda is required to provide post-approval updates on safety and efficacy analyses for TOURMALINE-MM1 and some other already ongoing studies to demonstrate the treatment's long-term effects.

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year

Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index component of the Dow Jones Sustainability Asia Pacific Index, the Asia Pacific version of the Dow Jones Sustainability Indices (“DJSI”) and one of the world’s premier indices for Soc...

Eisai ramps up precision med efforts with new unit

A team of 90 scientists at a newly formed institute in Andover, MA will be tasked with accelerating drug discovery efforts in areas like dementia and cancer. 

Quick Search
Advertisement
 

review and buy Top Pharmaceutical Companies in Japan market research data and corporate reports here